Background
==========

Oxidative stress has been considered as a potential pathogenic mechanism for initiation and progression of atherosclerotic disease \[[@B1]\]. Excessive production of reactive oxygen species, a mediator of the oxidative stress cascade, leads to release of inflammatory cytokines, oxidation of LDL and prothrombotic state, and finally results in endothelial dysfunction and atherosclerotic vascular lesions \[[@B2]-[@B4]\]. Adequate dietary, enzymatic and nonenzymatic antioxidant supplementation may be effective in lowering oxidative stress. Although most trials with antioxidants in experimental models of atherosclerosis have demonstrated that this treatment is able to retard the progression of atherosclerosis, the results of clinical trials are equivocal \[[@B5]\]. Differences in the definition criteria of patients who are potential candidates for antioxidant treatment, type and dosage of antioxidant supplementation, as well as outcome measures may explain this variability. Since oxidative stress is activated by many cardiovascular risks factors such as hypertension, hyperglycemia, dyslipidemia and smoking, patients with multiple cardiovascular risk factors could obtain beneficial effect from antioxidant treatment \[[@B6]-[@B9]\]. Additionally, combinations of dietary antioxidants (vitamin C and vitamin E) with carrier in mitochondrial oxidative phosphorylation (coenzyme Q~10~) and trace elements essential for adequate function of many antioxidant enzymes (selenium) may underlie the synergism between them and amplify the positive antioxidant effect. The present study was designed to determine the effect of antioxidant supplementation with vitamin C, vitamin E, coenzyme Q~10~and selenium on arterial compliance, inflammatory and metabolic parameters in patients with multiple cardiovascular risk factors.

Methods
=======

In a randomized, placebo-controlled study 70 patients with at least two cardiovascular risk factors were recruited from the hypertension outpatient clinic at E.Wolfson Medical Center for study participation. Screening procedures included physical examination, complete blood chemistry; complete blood count, urinalysis and electrocardiogram.

Cardiovascular risk factors were defined using the National Cholesterol Education Program risk factors categories: hypertension (systolic blood pressure \> = 140 mm Hg and/or diastolic BP \> = 90 mm Hg and/or taking antihypertensive medication); diabetes (fasting plasma glucose level \> = 126 mg/dl on at least two blood samples and/or taking glucose lowering agents, hypertriglyceridemia (\> = 1.7 mmol/l); low HDL cholesterol level (\< 1.03 mmol/l in men and \< 1.3 mmol/l in women); or current cigarette smoking.

Patients with a history of unstable angina, MI, CVA or major surgery within the six months preceding entrance to the study were excluded. Patients with unbalanced endocrine disease or any disease that might affect absorption of medications were excluded, as were patients with plasma creatinine \> 2 mg/dl, elevation of liver enzymes to more that twice the upper normal limit, and electrolyte abnormalities. Patients included in the study were stabilized on their previous medical treatment in the outpatient clinic for up to three months, and an effort was made not to change treatment during the study. All concomitant medications were kept stable to prevent possible effects on the study parameters.

The study was approved by the Institutional Review Board and the patients signed a full informed consent.

Study participants were randomly assigned to two groups. Group 1 received oral supplementation with 2 capsules per day of Mid Life Guard, SupHerb, Israel. In each capsule vitamin C (500 mg) vitamin E (200 iu), co-enzyme Q10 (60 mg) and selenium (100 mcg), Group 2 received matching placebo(SupHerb) for 6 months.

Biochemical parameters
----------------------

Blood sampling for full chemistry and metabolic parameters, including fasting glucose, lipid profile, HbA1C, hs-CRP, homocysteine, endothelin, aldosterone, plasma renin activity was performed at baseline and at the end of the study.

Arterial Elasticity Measurements
--------------------------------

Arterial compliance measures were performed after an overnight fast and before blood sampling. Measures were performed between 8 and 10 AM, in a quiet, temperature -controlled laboratory. With the subject in a supine position, radial arterial waveforms were recorded for 30 sec. The pressure transducer amplifier system was connected to a specially designed device (Model CR-2000, Hypertension Diagnostics Inc. Eagan, MN). The passive transient response of the arterial vasculature to the initial loading conditions was determined by analyzing the diastolic portion of the pressure pulse-wave form. This technique, which has been validated for its reproducibility and used extensively \[[@B10]-[@B12]\], was performed with a simple noninvasive radial pulse wave recording and computer analysis of the diastolic decay. This provides separate assessment of the large artery or capacitive compliance (C1) and small artery reflective or oscillatory compliance (C2). Cardiac output and stroke volume were computed from the average waveforms. Systemic vascular resistance (SVR) is calculated as mean arterial pressure (MAP) divided by cardiac output (CO). Arterial elasticity was determined at the baseline visit and at the 3- and 6 -month on-treatment visits.

Sample size
-----------

The primary endpoint in the present study was the paired difference in small artery elasticity (SAEI) within each group. With a sample size of n = 33 in each group, the present study was designed to have not less than 80% power to detect a true, within group difference of at least 1.2 ± 2 mL/mm Hg × 100 in SAEI in each of the two treatment groups assuming a two-tailed alpha of 0.025 (preserving to overall study alpha at 0.05).

Statistical analysis
--------------------

Analysis of data was carried out using SPSS 10.0 statistical analysis software (SPSS Inc., Chicago, IL, USA, 1999). For continuous variables, such arterial compliance parameters and biochemistry data, descriptive statistics were calculated and reported as mean ± standard deviation. Normalcy of distribution of continuous variables was assessed using the Kolmogorov-Smirnov test (cut off at p = 0.01). Categorical variables such as sex and concomitant illnesses were described using frequency distributions and are presented as frequency (%). The t-test for independent samples was used to compare continuous variables by treatment group. Categorical variables were compared by treatment group using the chi square test (exact as needed). General linear modeling was used to compare post-treatment continuous variables that differed by treatment group at baseline, including treatment group as the fixed factor and the baseline value of the modeled variable as a covariate. All tests are two-sided and considered significant at p \< 0.05.

Results
=======

Demographic and clinical characteristics of the 70 patients with multiple cardiovascular risk factors are presented in Table [1](#T1){ref-type="table"}. Group 1 included 36 patients who received oral daily supplementation with vitamin C, vitamin E, coenzyme Q~10~and selenium. Group 2 included 34 patients who received placebo. As can be seen, both groups were similar with respect to age, sex, BMI, presence of cardiovascular risk factors, baseline blood pressure level and arterial elasticity parameters. Concomitant medications were similarly distributed in both groups at the start and end of the study.

###### 

Baseline demographic and clinical characteristics of study patient

  Variables                                  Patients received antioxidants   Patients received placebo   p value
  ------------------------------------------ -------------------------------- --------------------------- ---------
  Age (y)                                    62.17 ± 6.21                     62.97 ± 5.09                0.559
                                                                                                          
  Male/Female                                21/13                            15/21                       0.678
                                                                                                          
  BMI                                        30.10 ± 4.04                     29.83 ± 5.06                0.968
                                                                                                          
  Current smokers, n (%)                     8 (23.53%)                       10 (27.8%)                  0.684
                                                                                                          
  Hypertension, n (%)                        25 (75.53%)                      26 (72.2%)                  0.902
                                                                                                          
  Diabetes mellitus, n (%)                   13 (38.23%)                      9 (25%)                     0.233
                                                                                                          
  Dyslipidemia, n (%)                        26 (76.47%)                      28 (77.8%)                  0.896
                                                                                                          
  Obesity, n (%)                             17 (50%)                         14 (38.9%)                  0.349
                                                                                                          
  Family history of IHD, n (%)               26 (76.5%)                       27 (75%)                    0.886
                                                                                                          
  Concomitant medication:                                                                                 
                                                                                                          
   Statins (%)                               25 (73.53%)                      27 (75%)                    0.888
                                                                                                          
   ACEIs/ARBs (%)                            19(55.88%)                       12 (33.33%)                 0.150
                                                                                                          
   Diuretics (%)                             6 (17.64%)                       2 (5.56%)                   0.112
                                                                                                          
   B-blockers (%)                            19 (55.89%)                      16 (44.4%)                  0.338
                                                                                                          
   CCB-blockers (%)                          10 (29.41%)                      11 (30.56%)                 0.917
                                                                                                          
   Aspirin (%)                               13 (38.23%)                      16 (44.45%)                 0.598
                                                                                                          
  Baseline systolic BP (mm/Hg)               125.2 ± 25.4                     138.0 ± 20.8                0.203
                                                                                                          
  Baseline diastolic BP (mm/Hg)              78.4 ± 11.7                      75.9 ± 7.8                  0.291
                                                                                                          
  Baseline fasting glucose (mg/dl)           127.1 ± 52.8                     118.9 ± 42.2                0.476
                                                                                                          
  Baseline HbA~1~C (%)                       7.1 ± 1.7                        6.8 ± 1.4                   0.391
                                                                                                          
  Baseline total cholesterol (mg/dl)         201.5 ± 53.1                     198.8 ± 50.8                0.833
                                                                                                          
  Baseline LDL Cholesterol (mg/dl)           117.5 ± 43.7                     118.3 ± 47.1                0.945
                                                                                                          
  Baseline HDL%                              22.1 ± 4.6                       26.0 ± 5.4                  0.004
                                                                                                          
  Baseline triglycerides (mg/dl)             189.5 ± 95.0                     122.8 ± 56.5                0.001
                                                                                                          
  Baseline hs-CRP (mg/dl)                    1.84 ± 2.9                       1.35 ± 1.6                  0.616
                                                                                                          
  Baseline endothelin(fmol/ml)               0.7 ± 2.6                        1.4 ± 4.8                   0.293
                                                                                                          
  Baseline homocysteine (μmol/l)             9.2 ± 2.8                        8.8 ± 3.1                   0.486
                                                                                                          
  Baseline renin (ng/ml/hr)                  1.8 ± 3.4                        1.5 ± 1.8                   0.695
                                                                                                          
  Baseline aldosteron (pg/ml)                7.4 ± 5.6                        6.7 ± 4.5                   0.590
                                                                                                          
  Baseline urine cathacholamines (mg/24 h)   24.74 ± 22.4                     19.5 ± 12.1                 0.278

Changes in hemodynamic and arterial elasticity parameters in patients treated with antioxidants
-----------------------------------------------------------------------------------------------

Table [2](#T2){ref-type="table"} shows six month follow-up of hemodynamic and arterial elasticity parameters in patients received antioxidants. Systolic blood pressure (SBP) decreased significantly from 145.2 +/- 25.4 at baseline to 136.1 +/- 22.3 mmHg after 6 months of treatment (p \< 0.001). Diastolic blood pressure (DBP) decreased significantly during the treatment period from 78.4 +/- 11.7 to 75.0 +/- 12.3 mmHg (p \< 0.034). Heart rate did not change during the study.

###### 

Change from baseline in homodynamic, arterial stiffness and metabolic variables in each group

  Variables                     Patients received antioxidants   Patients received placebo                                              
  ----------------------------- -------------------------------- --------------------------- -------- ---------------- ---------------- -------
  Systolic BP (mm/Hg)           145.2 ± 25.4                     136.1 ± 22.3                0.001    138.0 ± 20.8     135.0 ± 21.6     0.257
                                                                                                                                        
  Diastolic BP (mm/Hg)          78.4 ± 11.7                      75.0 ± 12.3                 0.034    75.9 ± 7.8       75.0 ± 10.3      0.493
                                                                                                                                        
  LAEI(ml/mm Hg × 10)           11.0 ± 4.4                       12.7 ± 4.7                  0.006    12.9 ± 6.2       11.3 ± 4.3       0.151
                                                                                                                                        
  SAEI(ml/mm Hg × 100)          3.3 ± 1.9                        4.7 ± 2.7                   0.0001   3.6 ± 1.6        3.7 ± 1.9        0.732
                                                                                                                                        
  SVR(dynes•sec/cm5)            1817.0 ± 751.5                   1617.3 ± 305.2              0.102    1594.9 ± 351.3   1638.7 ± 311.3   0.533
                                                                                                                                        
  Glucose(mg/dl)                127.0 ± 52                       129 ± 62                    0.535    118.9 ± 42       123.2 ± 55       0.496
                                                                                                                                        
  HbA~1~C(%)                    7.08 ± 1.69                      6.33 ± 2.3                  0.022    6.82 ± 1.44      6.86 ± 1.66      0.767
                                                                                                                                        
  Total Cholesterol(mg/dl)      201.5 ± 53.1                     180.7 ± 58.3                0.074    197.12 ± 50      186.80 ± 37.78   0.125
                                                                                                                                        
  Triglycerides(mg/dl)          189 ± 94                         170.4 ± 72                  0.058    124.5 ± 56.5     127.83 ± 46.7    0.645
                                                                                                                                        
  HDL%                          22.1 ± 4                         26.2 ± 10                   0.022    26 ± 5.4         27.11 ± 5.5      0.212
                                                                                                                                        
  LDL Cholesterol(mg/dl)        116.8 ± 44.4                     103.4 ± 47                  0.13     117.91 ± 47.9    109.0 ± 33.1     0.135
                                                                                                                                        
  hs-CRP(mg/dl)                 1.94 ± 3                         0.62 ± 0.77                 0.222    1.44 ± 1.59      0.95 ± 0.90      0.271
                                                                                                                                        
  Renin (ng/ml/hr)              1.79 ± 3.4                       2.27 ± 2.6                  0.494    1.36 ± 1.55      1.91 ± 1.87      0.149
                                                                                                                                        
  Aldosterone(pg/ml)            7.38 ± 5.6                       8.2 ± 5.06                  0.354    6.70 ± 4.5       7.00 ± 3.84      0.638
                                                                                                                                        
  Homocysteine(μmol/l)          9.24 ± 2.82                      9.19 ± 2.83                 0.911    8.75 ± 3.04      9.11 ± 3.3       0.139
                                                                                                                                        
  Ur cathacholamines(mg/24 h)   24.74 ± 21                       28.5 ± 19                   0.118    19.54 ± 12       22 ± 20          0.283
                                                                                                                                        

LAEI increased from 11.0 +/- 4.4 to 12.7 +/- 4.7 ml/mm Hg × 100 after 6 months of treatment (p \< 0.006) (Figure [1](#F1){ref-type="fig"}). SAEI increased significantly during the study from 3.3 +/- 1.9 to 4.7 +/- 2.7 ml/mm Hg × 100 (p \< 0.0001) (Figure [2](#F2){ref-type="fig"}). Although SVR decreased by 11% during the treatment period, this decrease did not reach statistical significance (p = 0.102) (Table [2](#T2){ref-type="table"}).

![**LAEI by groups during 6-month follow-up**.](1743-7075-7-55-1){#F1}

![**SAEI by groups during 6-month follow-up**.](1743-7075-7-55-2){#F2}

Changes in hemodynamic and arterial elasticity parameters in the control group
------------------------------------------------------------------------------

As shown in Table [2](#T2){ref-type="table"}, systolic blood pressure as well as diastolic blood pressure did not change significantly during the study (p = 0.257 and p = 0.493, respectively).

Neither LAEI nor SAEI improved significantly during the treatment period. LAEI was 12.9 +/- 6.2 ml/mmHg × 100 at baseline and 11.3 +/- 4.3 ml/mmHg × 100 after 6 months of follow-up (p = 0.151) (Figure [1](#F1){ref-type="fig"}). SAEI was 3.6 +/- 1.5 at baseline and 3.7 +/- 1.9 ml/mmHg × 100 at the end of the study (p = 0.732) (Figure [2](#F2){ref-type="fig"}). SVR tended to increase during the study from 1594.7 +/- 351.3 to 1638.7 +/- 311.3 dyne × sec × cm, however this increase did not reach statistical significance (p = 0.533) (Table [2](#T2){ref-type="table"}).

Changes in metabolic and inflammatory parameters during 6-month treatment period
--------------------------------------------------------------------------------

As shown in Table [2](#T2){ref-type="table"}, levels of HbA~1~C decreased significantly from 7.08 ± 1.69% to 6.33 ± 2.3% (p = 0.022) in patients received antioxidants. Additionally, significant increase in HDL-cholesterol (p = 0.022) and marginal declines in triglycerides (p = 0.058) as well as total cholesterol levels (p = 0.074) were observed in antioxidant treated patients.

Metabolic parameters including HbA~1~C, triglycerides, total cholesterol, HDL-cholesterol and CRP did not change in placebo group during the study.

Discussion
==========

The present randomized, placebo controlled study demonstrates that antioxidant supplementation with vitamin C, vitamin E, coenzyme Q~10~and selenium significantly increased large and small artery elasticity in patients with multiple cardiovascular risk factors. This beneficial vascular effect was associated with an improvement in glucose and lipid metabolism as well as significant decrease in blood pressure.

Assessment of arterial function and structure can serve as a surrogate endpoint for prediction of morbid events and for estimation of success of treatment. Pulse wave contour analysis using the modified Windkessel model is one of several noninvasive methods for estimation of arterial properties. Numerous studies performed with the HDI CR-2000 equipment have shown good correlation to age, cardiovascular risk factors and markers of disease \[[@B13]\]. Therapeutic interventions with medications like statins, angiotensin II receptor blocking agents as well as weight loss, have also shown improvement in LAEI and SAEI which may suggest lowering of cardiovascular risk. Nevertheless, no major prospective study associating arterial elasticity with cardiovascular events has been performed. Although PWA using the modified Windkessel model has some limitations, this method provides complementary information about vascular health.

The favorable vascular effect of antioxidants has been observed *in vitro*and in animal models of atherosclerosis \[[@B14]-[@B16]\]. However, data on long-term vascular impact of antioxidant supplementation in humans are limited and controversial. The findings of the present study concur with those of previous study that has shown substantial reduction in the progression of common carotid atherosclerosis during three year treatment with combined supplementation of both vitamin E and vitamin C \[[@B17]\]. Additionally, the beneficial effect of antioxidant supplementation on LDL oxidation and endothelial flow has been demonstrated \[[@B18],[@B19]\]. Moreover several prospective randomized controlled clinical trials such as Cambridge Heart Antioxidant Study, Secondary Prevention with Antioxidants of Cardiovascular Disease in End-stage Renal Disease study and Cholesterol Lowering Atherosclerosis Study reported that the administration of antioxidants reduced the risk of cardiovascular disease \[[@B20]-[@B22]\]. Nevertheless, subsequent large interventional studies do not support a benefit from antioxidant supplementation \[[@B23],[@B24]\]. These clinical trials have demonstrated that vitamin E alone or in combination has no effect on the risk of death or prevention of cardiovascular disease. Moreover, a dose-response meta-analysis has shown that high-dosage vitamin E supplementation was associated with a small but statistically significant increased risk for mortality \[[@B25]\]. The lack of benefit seen in these clinical trials does not disprove the central role of oxidative stress in atherosclerosis and justify investigating the overall clinical impact of antioxidant treatment.

Although the anti-atherogenic effect of antioxidants has been assessed in several experimental studies, the mechanisms by which these agents inhibit atherosclerosis remain to be clarified. Combined supplementation of vitamin E and C have been shown to inhibit DNA oxidation by H~2~O~2~in human lymphocytes, to enhance endogenous plasma and tissue antioxidant defenses and restore endothelium-dependent vasoactivity \[[@B18],[@B26],[@B27]\]. Coenzyme Q~10~which plays an essential role as an electron carrier in mitochondrial oxidative phosphorylation, improves endothelial dysfunction in diabetic patients \[[@B28]\]. Finally, selenium as a determinant of antioxidative glutathione peroxidase 1 expression and activity, provides significant protection of the coronary artery endothelium against damage by oxidative stress \[[@B29]\].

The findings of the present study concur with those of previous studies that have shown substantial reduction in blood pressure and improvement in long-term glycaemic control with oral CoQ supplementation, reduction in plasma glucose and insulin resistance with high doses of vitamin E supplementation and significant reduction in blood pressure levels with vitamin E as well as vitamin C in hypertensive patients \[[@B30]-[@B33]\]. Nevertheless, which particular antioxidant or combination of antioxidants is responsible for the favorable metabolic effect in the present study remains uncertain. Additionally, we cannot exclude the possibility that specific antioxidant combination which was used in the present study, has a contributory effect of on blood pressure, glucose and lipid homeostasis as well as on improvement of vascular elasticity.

In the present study, we did not observe significant changes in humoral factors such as homocystein, endothelin, aldosterone and renin in subjects received antioxidant supplementation. Levels of urine cathecholamines also did not change during the treatment period. These findings emphasize a previously published data which have shown that patophysiologic mechanism of antioxidants action is independent of the changes in plasma concentration of blood pressure modulators, such as renin, aldosterone, endothelin \[[@B34]\], although the precise mechanism for antioxidant action on the vasculature remains to be elucidated.

Our study has several limitations. First, the present study contains relatively small number of participants and larger studies are required to establish the beneficial vascular effect of antioxidant supplementation. Second, we did not measure plasma levels of the antioxidants which would have added the information regarding treatment compliance and would have elucidated the pathophysiology for vascular action of antioxidants. Furthermore, since the present study has focused on patients with multiple cardiovascular risk factors, the application of our findings to other patient populations remains uncertain.

Conclusion
==========

We have demonstrated that combined antioxidant supplementation with vitamin C, vitamin E, coenzyme Q~10~and selenium has beneficial effect on glucose and lipid metabolism, blood pressure and arterial compliance in patients with multiple cardiovascular risk factors. The findings of the present study justify investigating the overall clinical impact of antioxidant treatment in this population.
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